Northwest Biotherapeutics NWBO

OTC: NWBO | ISIN: US66737P6007   23/09/2026
0,160 USD (-2,09%)
(-2,09%)   23/09/2026

6 augustus 2026 · Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company · Persbericht

8 juli 2026 · Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses · Persbericht

2 juli 2026 · Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting · Persbericht

30 april 2026 · Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform · Persbericht

21 april 2026 · Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic · Persbericht

20 november 2025 · Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility · Persbericht

24 oktober 2025 · Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed · Persbericht

27 augustus 2025 · Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. · Persbericht

18 augustus 2025 · Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman · Persbericht

11 juni 2025 · Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments · Persbericht

Mijn selecties